OPPORTUNITIES FOR LOGISTIC REORGANISATION OF THE HOSPITAL PHARMACY WITH NEW CARE MODES: STOCK MANAGEMENT (SM) AND HOME DELIVERY (HD)
1ISG-006
OPPORTUNITY TO STUDY ADHERENCE AND PERSISTENCE WITH HOME DELIVERY (HD) - REAL WORLD DATA (RWD) AND REAL WORLD EVIDENCE (RWE) ANALYSIS
1ISG-005
DEPARTMENT COMPUTERISED PHARMACEUTICAL CABINET: RESULTS OF DEMATERIALIZATION AND TRACEABILITY OF DRUGS IN OBSTETRICS AND GYNECOLOGY
1ISG-004
HOME DELIVERY - EFFICIENCY, ECONOMY AND CUSTOMER SATISFACTION OUTCOMES - COMPARISON OF ASSISTANCE MODELS
1ISG-003
PROTOCOL FOR THE OPTIMISATION OF PHARMACEUTICAL VALIDATION IN HOSPITALIZED PATIENTS
1ISG-002
MEDICATION WASTE IN AN ORTHOPAEDIC DEPARTMENT: EFFECT OF PATIENT'S OWN MEDICATION USE AND SELF-ADMINISTRATION DURING HOSPITALISATION AND THE VIEWS OF PATIENTS AND HOSPITAL STAFF
1ISG-001
ECONOMIC IMPACT GENERATED BY NATALIZUMAB OPTIMIZATION
1ISG-004
ASSESSMENT OF CUSTOMER SATISFACTION WITH HOSPITAL PHARMACY SERVICES IN ESTONIA
1ISG-013
Users’ expectations and opinions on a computerised physician order entry (CPOE) system before and after its implementation
1ISG-008
OPTIMISATION PROGRAMME OF OMALIZUMAB TREATMENT FOR CHRONIC IDIOPATHIC URTICARIA
1ISG-012
ECONOMIC EVALUATION OF DOSE BANDING IN INMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB
1ISG-009
IMPLEMENTATION AND EVALUATION OF TELEPHARMACY DURING COVID-19 PANDEMIC IN AN ACADEMIC MEDICAL CITY : PAVING THE WAY FOR TELEPHARMACY
1ISG-007
ECONOMIC SAVINGS FROM WEIGHT-BASED DOSING OF PEMBROLIZUMAB: WHAT IS THE IMPACT IN A TERTIARY HOSPITAL?
1ISG-006
ESTIMATION OF DRUG COST AVOIDANCE IN CLINICAL TRIALS OF NON-SMALL CELL LUNG CANCER
1ISG-003
IMPACT OF TELEPHARMACY AND COMMUNITY PHARMACY REMOTE-DISPENSING ON PATIENTS ON ORAL ANTINEOPLASTIC AGENTS
